At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
EXT608 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
EXT608 in Human Healthy Adults; A First-in-Human, Randomized, Double-Blind, Placebo-controlled, Single Dose Escalation Study
In Brief
A Phase 1 clinical trial evaluating EXT608 and Placebo for Safety Issues. Completed, enrolled 24 participants across 1 site.
Detailed Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose safety and tolerability study of EXT608 in healthy subjects. There will be up to 6 sequential dose escalation cohorts of 4 participants. In each cohort 3 participants will receive EXT608 and 1 participant will receive placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSafety Issues
CountriesUnited States
Timeline
Phase 1CompletedFinished
2023202420252026
First PostedJun 2022
Enrollment StartJul 2022
Primary CompletionJun 2023
TodayJul 2026
First PostedJun 7, 2022
Enrollment StartJul 21, 2022
Primary CompletionJun 13, 2023
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 4.1 years ago
Interventions
EXT608drug
EXT608 is an investigational drug administered via subcutaneous injection
Placeboother
matching placebo administered via subcutaneous injection